Approval · Notice of Compliance 2566 · 2001
ADVAIR: Notice of Compliance 2566
Issued December 21, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2566
- Date
- December 21, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage form: inhalation aerosol
- Therapeutic class
- Broncholdilator and corticosteroid for oral inhalation
Products in this notice
Medicinal ingredients
- FLUTICASONE PROPIONATE 50 MCG per ACT
- SALMETEROL XINAFOATE 25 MCG per ACT
- FLUTICASONE PROPIONATE 125 MCG per ACT
- FLUTICASONE PROPIONATE 250 MCG per ACT